Organogenesis Holdings Inc. Plans New $100 Million Biomanufacturing Facility In Smithfield, Rhode Island To Expand Wound Care And Regenerative Medicine Production

Organogenesis Holdings Inc. Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on developing, manufacturing, and commercializing products for the Advanced Wound Care and Surgical & Sports Medicine markets, announced plans to begin the design and construction of a new biomanufacturing facility in Smithfield, Rhode Island.

The new 122,000-square-foot facility, located at 100 Technology Way, will include state-of-the-art manufacturing, laboratory, warehousing, and distribution capabilities. It is intended to support Organogenesis’ current advanced wound care product portfolio and future growth initiatives. Initial investments will focus on expanding the infrastructure necessary to resume commercial production of Dermagraft®, a human fibroblast-derived dermal substitute approved by the FDA for treating diabetic foot ulcers (DFUs). Additional investments will enhance the company’s regenerative medicine portfolio, including the Apligraf® and PuraPly® brands.

Gary S. Gillheeney Sr. Gary S. Gillheeney Sr., President, CEO, and Chair of the Board, stated that the Smithfield facility represents the company’s commitment to expanding its presence in New England, a major hub for life sciences. He added that the facility is expected to serve as a catalyst for Rhode Island’s life sciences industry and to encourage continued regional collaboration in biotechnology.

Mark A. Turco, MD Mark A. Turco, President and CEO of the Rhode Island Life Science Hub, welcomed Organogenesis to the state, noting that the new facility will produce advanced biomedical products, create high-quality jobs, and strengthen Rhode Island’s growing life sciences community.

Gillheeney also highlighted that the facility will allow Organogenesis to stay at the forefront of regenerative medicine by providing additional capacity to expand multiple technology platforms and deliver new innovations to patients. The company plans to invest approximately $100 million over several years in further improvements at the Smithfield site. Once operational, the facility is expected to support over 200 full-time positions, with potential for additional job creation as the site grows.

This strategic expansion underscores Organogenesis’ commitment to innovation, patient care, and long-term growth in the regenerative medicine sector, positioning the Smithfield facility as a cornerstone of Rhode Island’s biomanufacturing and life sciences landscape.

Also Read :

Organogenesis Holdings Inc. Confirms FDA Type-B Meeting Outcome, Plans Rolling BLA Submission For ReNu Before December 2026